Report Interpretation

Overview

This 1H26 model update argues that WuXi AppTec’s faster growth is becoming higher quality: commercial manufacturing is expanding faster than early-stage work, margins are improving through mix and utilization, and backlog supports continued growth. Bernstein therefore raises forecasts and maintains Outperform.

Core views

Bernstein’s central thesis is that WuXi AppTec’s 1H26 growth was led by higher-value commercial manufacturing rather than solely by early-stage activity. WuXi Chemistry grew 53% YoY, with small-molecule D&M up 73% and TIDES up 44%. Within D&M, Phase III and commercial projects increased 18% YoY to 189, compared with 9% growth in early-stage projects to 3,542 in 2Q26. The institution views this as a favorable mix shift toward more valuable manufacturing revenue. It expects WuXi Chemistry revenue to reach CNY28.1bn in 2H26E, up 39% YoY, driven by projected 39% growth in small-molecule D&M and 54% growth in TIDES. TIDES demand is described as broadening after its 2024 slowdown. Customer growth accelerated from 15% in 2024 to 39% in 1H26, while molecule/project growth accelerated from 22% to 68%. Bernstein interprets the simultaneous rebound as evidence that growth is extending beyond scale-up of a limited group of existing molecules. Backlog rose 25% YoY to roughly CNY66bn in 2Q26 despite 48% revenue growth, which the report considers evidence of resilient demand and visibility into FY27. However, one customer continued to account for more than 10% of revenue. Profitability strengthened materially. Group gross margin rose to 53.2% in 1H26 from 43.8% in 1H25, while WuXi Chemistry’s margin rose to 55.8% from about 48.2%-48.3%; WuXi Testing’s margin increased to 37.7% from 26.5%. Management attributed the gains to process optimization, higher utilization and the larger late-stage/commercial revenue mix, rather than one-off factors. Bernstein therefore treats the improvement as sustainable into 2H26. Its updated assumptions include adjusted gross margin of 54%, versus 45% in 1H25, and adjusted net margin of 38%, versus 30%. The report views higher investment spending as a demand-led expansion rather than excess capacity. FY26 CapEx guidance was raised to CNY7.5-8.5bn from CNY6.5-7.5bn, and the new Changzhou site came online ahead of schedule. Management also indicated a greater global focus for future capacity. Small-molecule reactor volume is expected to reach about 5,000m³ by end-2026 and TIDES reactor volume 130kL. Bernstein believes backlog growth to CNY66.4bn and stronger utilization support this investment cycle and make it a positive indicator for mid-term revenue growth. On the financial model, Bernstein raises FY26 revenue to CNY60.5bn from CNY53.4bn and FY26 EPS to CNY7.9 from CNY6.3. FY27 revenue rises to CNY75.2bn from CNY63.8bn and EPS to CNY9.6 from CNY7.4; FY28 revenue rises to CNY87.8bn from CNY75.0bn and EPS to CNY11.0 from CNY8.7. These changes represent revenue upgrades of 13%, 18% and 17% and EPS upgrades of 24%, 30% and 26% for FY26-FY28, respectively. The report estimates FY26 core EBIT at CNY26.8bn, up CNY5.4bn, and FY26 FCF at CNY13.5bn, within management’s revised CNY13.5-14.5bn guidance. The 12-month CNY target rises to CNY205 from CNY168, with the report citing 27% upside to the then-current market price; the HK target rises to HKD247 from HKD204. Bernstein uses an equal-weight blended valuation: a DCF-derived CNY206 value using a 10.6% WACC and 2.5% terminal growth rate, a CNY209 P/E value using 23x one-year-forward P/E, and a CNY198 EV/EBITDA value using 16x one-year-forward EV/EBITDA. The HK target applies a 2026 year-to-date stock-price premium of 1.21 to the CNY target framework.

Analysis framework

Bernstein assesses 1H26 operating results by tracing segment growth, project-stage mix, customer and molecule breadth, backlog, utilization and margins. It then updates revenue, earnings, cash-flow and capacity assumptions, and derives a blended target price from DCF, forward P/E and forward EV/EBITDA methods.

Methodology notes

• Industry AnalysisVolume-price decomposition

  Revenue growth is assessed through segment, project-stage, customer and molecule growth, with emphasis on the commercial-manufacturing mix.

  The report uses operating-volume and mix indicators to explain why revenue growth and margins may be more durable than a simple topline comparison suggests.

• Corporate Fundamentals and FinanceOperating and Financial Leverage Analysis

  Operating leverage, utilization, process optimization and revenue mix are used to explain gross-margin, net-margin and FCF upgrades.

  The report argues that higher utilization and a greater share of commercial work allow profitability to rise faster than revenue.

• Valuation methodsDCF (Discounted Cash Flow)

  A DCF valuation using a 10.6% WACC and 2.5% terminal growth rate contributes one-third of the target price.

  The method estimates the present value of forecast free cash flow and terminal value to produce a CNY206 valuation outcome.

• Valuation methodsP/E and PEG Valuation

  A one-year-forward P/E multiple of 23x produces a CNY209 valuation outcome.

  The report applies a forward earnings multiple to its updated net-income forecast.

• Valuation methodsEV/EBITDA valuation

  A one-year-forward EV/EBITDA multiple of 16x produces a CNY198 valuation outcome.

  The report values operating earnings before interest, tax, depreciation and amortization, then adjusts for cash and debt to estimate shareholder value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd (603259.CH)

  Primary covered A-share security; target price is raised on stronger growth, margins and cash-flow expectations.

  Strengths

  Commercial small-molecule D&M and TIDES growth, backlog visibility, margin expansion and operating leverage.

  Comparison

  The report uses a 23x forward P/E and 16x forward EV/EBITDA target framework; it notes the stock traded at 19.5x one-year-forward P/E.

  Risks

  1260H litigation uncertainty, customer concentration and potential peptide-capacity oversupply.

• WuXi AppTec Co Ltd (2359.HK)

  Primary covered H-share security; its target is derived using a 2026 YTD stock-price premium of 1.21.

  Strengths

  Same operating and earnings drivers as the A-share listing.

  Comparison

  HKD247 target versus HKD199.00 closing price as of 11 Aug 2026.

  Risks

  1260H litigation uncertainty, customer concentration and potential peptide-capacity oversupply.

Key data

• WuXi Chemistry growth53% YoY in 1H26Primary contributor to group expansion.
• Small-molecule D&M growth73% YoY in 1H26Key driver of WuXi Chemistry acceleration.
• TIDES growth44% YoY in 1H26Customer growth reached 39% and molecule/project growth 68%.
• BacklogApproximately CNY66bn in 2Q26Up 25% YoY and cited as support for FY27 visibility.
• Group gross margin53.2% in 1H26Up from 43.8% in 1H25.
• FY26 revenue forecastCNY60.5bnRaised from CNY53.4bn; at the upper end of revised CNY58.5-60.5bn guidance.
• FY26 EPS forecastCNY7.9Raised from CNY6.3.
• FY26 adjusted FCF guidanceCNY13.5-14.5bnRaised from CNY10.5-11.5bn; Bernstein estimates CNY13.5bn.
• FY26 CapEx guidanceCNY7.5-8.5bnRaised from CNY6.5-7.5bn.

Impact & implications

Bernstein says stronger commercial-manufacturing mix, margin expansion and backlog support a higher sustainable earnings profile. It interprets the higher CapEx plan as preparation for mid-term demand rather than a sign of excess capacity, while retaining attention to litigation, customer concentration and industry supply expansion.

Risks

• The preliminary US-court injunction against enforcement of the 1260H designation is not final; the ultimate effect depends on litigation progress and the court’s final decision.
• One customer contributed more than 10% of revenue in both 1H25 and 1H26, so changes in that customer’s demand could materially affect financial performance.
• Peptide capacity is expanding across the industry; if supply growth exceeds demand growth, the market could face oversupply.

What to watch

• Progress and final outcome of the 1260H litigation.
• Whether the more than 10% revenue-contributing customer maintains demand.
• Backlog conversion and continued growth in WuXi Chemistry and TIDES.
• Execution of the raised CapEx plan, Changzhou ramp-up and global capacity expansion.
• Whether industry peptide-capacity additions outpace demand.